Trial Profile
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Asciminib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 12 Dec 2023 Results (n=115) assessing Efficacy, Safety, and Tolerability of Asciminib (ASC) Monotherapy in Patients (Pts) with Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (cutoff:Mar 14, 2023),presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 21 Mar 2023 Status changed from active, no longer recruiting to completed.